Go to the list of all blogs
Anna G's Avatar
published in Blogs
Mar 24, 2021
TickeronGET DAILY SIGNALS
Clorox (CLX, $185.95) shares downgraded at D.A. Davidson analyst

Clorox (CLX, $185.95) shares downgraded at D.A. Davidson analyst

Clorox  shares got a rating downgrade from D.A. Davidson on concerns about an expected slowdown in sales following a possible peak in demand during the depths of the COVID-19 pandemic.

The household products company’s shares were downgraded to neutral from buy by D.A. Davidson analyst Linda Bolton Weiser. She also cut her price target on the shares to $189 from $234.

According to Weiser, consensus estimates have been pricing in a 1.7% decline in sales for March, which may be too optimistic. 

Clorox had previously said it projects sales growth of + 5% to +9% for fiscal 2022. It expected  diluted earnings in the range of $7.70 to $7.95 a share. Both were upward revisions to the company’s summer forecast. But, Weiser mentioned that  there was a risk that Clorox would not raise and might even lower its guidance when it reports fiscal third-quarter results next month.

The analyst lowered her fiscal 2022 earnings per share expectations to $8.01 from $8.16, below the $8.21 average analyst estimate.

 

 

 

Related Ticker: CLX

CLX in upward trend: 10-day moving average crossed above 50-day moving average on November 03, 2026

The 10-day moving average for CLX crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

CLX moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLX advanced for three days, in 181 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

The Aroon Indicator entered an Uptrend today. In 75 of 193 cases where CLX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 39%.

Bearish Trend Analysis

The 10-day RSI Indicator for CLX moved out of overbought territory on November 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 12 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 55 cases where CLX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 55%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.

CLX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 10 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. CLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLX's P/B Ratio (134.314) is slightly higher than the industry average of (21.731). P/E Ratio (20.739) is within average values for comparable stocks, (16.288). Projected Growth (PEG Ratio) (1.019) is also within normal values, averaging (1.518). Dividend Yield (0.050) settles around the average of (0.032) among similar stocks. P/S Ratio (1.542) is also within normal values, averaging (1.902).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

Notable companies

The most notable companies in this group are Procter & Gamble Company (NYSE:PG), Colgate-Palmolive Company (NYSE:CL).

Industry description

Household/Personal Care companies sell products for home cleaning and/or personal hygiene and grooming purposes. Products of this industry include detergents, shampoos, soaps, cosmetics, fabric conditioners and infant care fragrances. Procter & Gamble, Unilever, Estee Lauder and Colgate-Palmolive are some of the biggest names in the business. A lot of the products become a necessary part of people’s daily routine, and therefore the industry is relatively less vulnerable to macroeconomic downturns. At the same time, product quality, consumer safety, and ease of use are extremely critical factors for a company to survive competition and earn recognition in this industry.

Market Cap

The average market capitalization across the Household/Personal Care Industry is 25.17B. The market cap for tickers in the group ranges from 60.48K to 384.17B. PG holds the highest valuation in this group at 384.17B. The lowest valued company is EOSS at 60.48K.

High and low price notable news

The average weekly price growth across all stocks in the Household/Personal Care Industry was -7%. For the same Industry, the average monthly price growth was 9%, and the average quarterly price growth was 18%. FRTT experienced the highest price growth at 18%, while BYAH experienced the biggest fall at -41%.

Volume

The average weekly volume growth across all stocks in the Household/Personal Care Industry was 2%. For the same stocks of the Industry, the average monthly volume growth was 79% and the average quarterly volume growth was 80%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 50
Price Growth Rating: 49
SMR Rating: 73
Profit Risk Rating: 86
Seasonality Score: 35 (-100 ... +100)
Related Portfolios: CONSUMER STAPLES ETFs
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a maker of detergent and cleaning products

Industry HouseholdPersonalCare

Industry
Household Or Personal Care
Address
1221 Broadway
Phone
+1 510 271-7000
Employees
7600
Web
https://www.thecloroxcompany.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.